Abstract

Cancelled - Analytical Automation in Cell and Gene Therapy

Stuart Macnab, Principal Scientist, Novartis

Drug development activities are classically include both manufacturing process development and analytical development. Whilst a process-focused development team may investigate innovative changes to a manufacturing process, the related analytical team will often have to perform a large amount of repetitive analytics requiring quick turn-around in support of the aforementioned investigations. When head-counts are fixed, the support required by process development can inhibit analytical experts from performing continued method development, and investigating state of the art techniques. Limited sample throughput of established methods, combined with the need to innovate at a process and analytical level, implies that automation should be pursued at the earliest opportunity.